• Iksuda Therapeutics raises $47m to progress ADC pipeline pharmatimes
    June 08, 2021
    Newcastle, UK-headquartered Iksuda Therapeutics has announced the closing of a $47m (£34m) financing round, with the funds to be used to support the advancement of its lead antibody drug conjugate (ADC) assets.
PharmaSources Customer Service